LivaNova: Q2 Earnings Insights
Shares of LivaNova (NASDAQ:LIVN) were unchanged after the company reported Q2 results.
Quarterly Results
Earnings per share were down 121.43% year over year to ($0.15), which beat the estimate of ($0.30).
Revenue of $182,200,000 declined by 34.27% from the same period last year, which beat the estimate of $169,730,000.
Looking Ahead
The upcoming fiscal year's EPS expected to be between $1.15 and $1.35.
The upcoming fiscal year's revenue expected to be between $900,000,000 and $1,008,000,000.
Conference Call Details
Date: Jul 29, 2020
Time: 07:00 AM
ET Webcast URL: https://edge.media-server.com/mmc/p/rznzyc3n
Recent Stock Performance
52-week high: $87.45
52-week low: $33.40
Price action over last quarter: Up 4.69%
Company Profile
U.K.-based LivaNova was born of a combination between Cyberonics in the U.S. and Sorin in Italy. The medical device firm is primarily focused on cardiovascular and cardiopulmonary solutions (with surgical heart valves, heart-lung machines, and oxygenation equipment) as well as neuromodulation devices for treatment-resistant epilepsy and depression. LivaNova derives roughly half of its revenue from the U.S. market, another 21% from Europe, and the remainder from the rest of the world.
